To address these challenges, we comprehensively screened for germline NBN variants in a large cohort of 4,183 pediatric B-ALL patients, experimentally characterized these variants using two phenotyping assays, and evaluated their association with B-ALL characteristics and treatment outcomes. Here, NBN is linked to acute lymphoblastic leukemia.